From: Randomized controlled trial design in rheumatoid arthritis: the past decade
Trial | Year published | Study drug | Mean disease duration at BL | Prior therapy | Duration |
---|---|---|---|---|---|
US 301 [5] | 1999 | LEF vs. MTX vs. PL | 7.0 (± 8.6) | MTX-naïve | 2 years |
MN 301 [16] | 1999 | LEF vs. SSZ vs. PL | 7.8 (± 8.6) | SSZ-naïve | 6 months + continuation |
ETN Phase 3 [4] | 1999 | ETN vs. PL | 12a | DMARD failures | 6 months |
ETN+MTX [3] | 1999 | ETN+MTX vs. PL+MTX | 13a | MTX > 6 months | 6 months (primary at 3) |
ATTRACT [6] | 1999 | INF+MTX vs. MTX+PL | 8.4 (± 7.7) | MTX > 3 months | 2 years |
MN 302 [15] | 2000 | LEF vs. MTX | 3.7 (± 3.2) | MTX-naïve | 1 year + continuation |
ERA [12] | 2000 | ETN vs. MTX | 0.9 (± 0.8) | MTX-naïve | 2 years |
TEMPO [13] | 2004 | ETN vs. MTX vs. ETN+MTX | 6.8 (± 5.5) | TNF-naïve | 2 years |
ASPIRE [10] | 2004 | INF vs. MTX vs. INF+MTX | 0.9 (± 0.8) | MTX-naïve | 1 year |
PREMIER [11] | 2006 | ADA vs. MTX vs. ADA+MTX | 0.7 (± 0.8) | MTX-naïve | 2 years |
ATTAIN [20] | 2005 | ABA+MTX vs. MTX+PL | 12.0 (± 8.5) | MTX > 3 months, TNF-I failure | 6 months + continuation |
AIM [19] | 2006 | ABA+MTX vs. MTX+PL | 8.5 (± 7.3) | MTX > 3 months, TNF-I-naïve | 6 months + continuation |
REFLEX [21] | 2006 | RTX+MTX vs. MTX+PL | 11.7 (± 7.7) | MTX > 3 months, TNF-I failure | 6 months + continuation |
DANCER [22] | 2006 | RTX+MTX vs. MTX+PL | 10.5a | MTX > 3 months, TNF-I-naïve | 6 months + continuation |